BR112023022315A2 - Quimeras direcionadas à desubiquitinase e métodos relacionados - Google Patents

Quimeras direcionadas à desubiquitinase e métodos relacionados

Info

Publication number
BR112023022315A2
BR112023022315A2 BR112023022315A BR112023022315A BR112023022315A2 BR 112023022315 A2 BR112023022315 A2 BR 112023022315A2 BR 112023022315 A BR112023022315 A BR 112023022315A BR 112023022315 A BR112023022315 A BR 112023022315A BR 112023022315 A2 BR112023022315 A2 BR 112023022315A2
Authority
BR
Brazil
Prior art keywords
chimeras
related methods
desubiquitinase
targeting
well
Prior art date
Application number
BR112023022315A
Other languages
English (en)
Inventor
C Ward Carl
K Nomura Daniel
Leard Dovala Dustin
Gang Liu
M Mckenna Jeffrey
Nichole Spradlin Jessica
A Tallarico John
Lydia Boike
Eberhard Schirle Markus
James Hesse Matthew
Melissa Pighetti
James Henning Nathaniel
Original Assignee
Novartis Ag
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ California filed Critical Novartis Ag
Publication of BR112023022315A2 publication Critical patent/BR112023022315A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

quimeras direcionadas à desubiquitinase e métodos relacionados. são aqui descritos compostos bifuncionais, bem como sais, hidratos, solvatos, profármacos, estereoisômeros ou tautômeros farmaceuticamente aceitáveis dos mesmos, que funcionam para recrutar certas desubiquitinases para uma proteína-alvo para modulação (por exemplo, estabilização) da proteína-alvo, bem como métodos de uso do mesmo.
BR112023022315A 2021-04-29 2022-04-29 Quimeras direcionadas à desubiquitinase e métodos relacionados BR112023022315A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163181796P 2021-04-29 2021-04-29
US202163186739P 2021-05-10 2021-05-10
US202163273118P 2021-10-28 2021-10-28
US202263311781P 2022-02-18 2022-02-18
PCT/US2022/027120 WO2022232634A1 (en) 2021-04-29 2022-04-29 Deubiquitinase-targeting chimeras and related methods

Publications (1)

Publication Number Publication Date
BR112023022315A2 true BR112023022315A2 (pt) 2024-02-20

Family

ID=81748638

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022315A BR112023022315A2 (pt) 2021-04-29 2022-04-29 Quimeras direcionadas à desubiquitinase e métodos relacionados

Country Status (8)

Country Link
EP (1) EP4329815A1 (pt)
JP (1) JP2024515828A (pt)
KR (1) KR20240004584A (pt)
AU (1) AU2022265718A1 (pt)
BR (1) BR112023022315A2 (pt)
CA (1) CA3216614A1 (pt)
IL (1) IL307863A (pt)
WO (1) WO2022232634A1 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008109031A (ru) 2005-08-11 2009-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы муковисцидозного трансмембранного регулятора проводимости
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
PL2168966T3 (pl) 2007-06-15 2017-06-30 Msd K.K. Pochodna bicykloaniliny
US20110035601A1 (en) 2007-12-21 2011-02-10 University Of Virginia Patent Foundation System, method and computer program product for protecting software via continuous anti-tampering and obfuscation transforms
EP2303885B1 (en) 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
CZ2009620A3 (cs) 2009-09-22 2011-04-06 Ústav makromolekulární chemie AV CR, v.v.i. Surovina pro výrobu polyurethanu a zpusob její výroby z odpadního polyurethanu
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011133953A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
MX2015007939A (es) 2012-12-19 2016-03-11 Novartis Ag Compuestos triciclicos para inhibir el canal de cftr.
EA201591175A1 (ru) 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения в качестве ингибиторов cftr
WO2018037350A1 (en) 2016-08-23 2018-03-01 Laurus Labs Limited Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof
KR20210020107A (ko) * 2018-06-13 2021-02-23 암피스타 테라퓨틱스 엘티디 UchL5 표적화를 위한 이중작용성 분자
EP3927726A1 (en) * 2019-02-21 2021-12-29 Locki Therapeutics Limited Survival-targeting chimeric (surtac) molecules
CA3164578A1 (en) * 2020-01-14 2021-07-22 Scott KANNER Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases

Also Published As

Publication number Publication date
CA3216614A1 (en) 2022-11-03
EP4329815A1 (en) 2024-03-06
JP2024515828A (ja) 2024-04-10
WO2022232634A1 (en) 2022-11-03
AU2022265718A1 (en) 2023-11-02
KR20240004584A (ko) 2024-01-11
IL307863A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
CO2021009695A2 (es) Conjugados de il-2 y métodos de uso de este
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
BR112019018648A2 (pt) Inibidores de jak contendo uma amida heterocíclica com 4 membros
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
BR112017007769A2 (pt) compostos e composições para modulação de atividades de cinase de egfr mutante
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
DOP2022000091A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
BR112021023824A2 (pt) Inibidor de proteína quinase dependente de dna
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
CY1125017T1 (el) Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho
BR112021019465A8 (pt) Compostos que têm como alvo prmt5
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
BR112022025061A2 (pt) Compostos que estabelecem como alvo brm e métodos de uso associados
EA202193015A1 (ru) Ингибиторы cdk
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
BR112017017350A2 (pt) proteína resistente a herbicidas, gene codificador e uso dos mesmos
BR112019004254A2 (pt) inibidores da dopamina-b-hidroxilase penetrantes da barreira hematoencefálica
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
BR112022000297A2 (pt) Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина